دورية أكاديمية
أعرض في EDS

The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats.

التفاصيل البيبلوغرافية
العنوان: The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats.
المؤلفون: Othman AM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Ashour Ibrahim I; Department of Biochemistry, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt., Saleh SM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Abo-Elmatty DM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Mesbah NM; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt., Abdel-Hamed AR; Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
المصدر: Biomedicines [Biomedicines] 2023 Dec 13; Vol. 11 (12). Date of Electronic Publication: 2023 Dec 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: Background: Type 2 diabetes mellitus (T2DM) is a chronic progressive disease due to insulin resistance. Oxidative stress complicates the etiology of T2DM. Saxagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, while Pioglitazone is a thiazolidinedione insulin sensitizer. This study aimed to assess the effect of Saxagliptin and Pioglitazone monotherapy and combination therapy on the biochemical and biological parameters in streptozotocin (STZ)-induced diabetic rats.
Methods: The study included thirty-five male albino rats. Diabetes mellitus was induced by intraperitoneal STZ injection (35 mg/kg). For a 1-month duration, rats were divided into five groups. Glucose homeostasis traits, lipid profiles, kidney functions, liver enzymes, and oxidative stress markers were measured. Gene expression of miRNA-29a, phosphoenolpyruvate carboxykinase (PEPCK), phosphoinositide-3-kinase (PI3K), and interleukin 1 beta (IL-1β) was assessed using qRT-PCR.
Results: At a 1-month treatment duration, combination therapy improves oxidative stress markers more than either drug alone. The combination therapy had significantly higher levels of SOD, catalase, and GSH and lower levels of MDA compared to the monotherapy. Additionally, the diabetic group showed a significant increase in the expression levels of miRNA-29a, PEPCK, and IL-1β and a significant decrease in PI3K compared to the normal control group. However, combination therapy of Saxagliptin and Pioglitazone was more effective than either Saxagliptin or Pioglitazone alone in reversing these results, especially for PEPCK and IL-1β.
Conclusions: Our findings revealed that combining Saxagliptin and Pioglitazone improves glycemic control and genetic and epigenetic expression profiles, which play an essential regulatory role in normal metabolism.
References: Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):423-37. (PMID: 16375695)
Nat Rev Endocrinol. 2020 May;16(5):276-283. (PMID: 32127696)
Hypertension. 2010 Jun;55(6):1444-53. (PMID: 20404217)
Life Sci. 2018 Oct 15;211:31-39. (PMID: 30195035)
Nat Rev Dis Primers. 2015 Jul 23;1:15019. (PMID: 27189025)
J Inflamm Res. 2016 Apr 11;9:27-38. (PMID: 27114714)
Medicine (Baltimore). 2018 Nov;97(46):e12633. (PMID: 30431561)
Diabetologia. 2009 Apr;52(4):723-32. (PMID: 19169664)
J Diabetes Investig. 2014 Jul;5(4):349-58. (PMID: 25411593)
Nat Rev Genet. 2006 Aug;7(8):606-19. (PMID: 16847462)
Diabetologia. 2015 May;58(5):900-11. (PMID: 25677225)
Transl Res. 2012 May;159(5):383-90. (PMID: 22500511)
Drug Dev Res. 2016 Sep;77(6):300-9. (PMID: 27520857)
Diabetes Obes Metab. 2011 Jul;13(7):604-14. (PMID: 21332626)
World J Diabetes. 2015 Apr 15;6(3):456-80. (PMID: 25897356)
Food Chem Toxicol. 2010 Aug-Sep;48(8-9):2448-53. (PMID: 20538037)
Am J Transl Res. 2019 Oct 15;11(10):6316-6325. (PMID: 31737185)
J Diabetes Investig. 2017 Mar;8(2):155-160. (PMID: 27860391)
Sci Rep. 2020 Feb 25;10(1):3373. (PMID: 32099009)
Int J Biol Sci. 2018 Aug 6;14(11):1483-1496. (PMID: 30263000)
J Endocrinol. 2014 Jul;222(1):R1-R10. (PMID: 24781254)
Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382)
Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):160-4. (PMID: 25593845)
Iran J Pharm Res. 2019 Fall;18(4):2144-2156. (PMID: 32184879)
Vasc Health Risk Manag. 2008;4(6):1221-7. (PMID: 19337535)
Phytomedicine. 2006 Jun;13(6):434-41. (PMID: 16716914)
PLoS One. 2015 Sep 18;10(9):e0137955. (PMID: 26383638)
Int J Mol Med. 2017 Apr;39(4):969-983. (PMID: 28260070)
J Mol Endocrinol. 2007 Apr;38(4):433-40. (PMID: 17446233)
PLoS Comput Biol. 2014 Aug 28;10(8):e1003798. (PMID: 25167060)
J Pharmacol Pharmacother. 2011 Oct;2(4):230-5. (PMID: 22025849)
Toxicol Appl Pharmacol. 2020 May 1;394:114956. (PMID: 32171571)
Postgrad Med. 2011 Jul;123(4):63-70. (PMID: 21680990)
J Med Life. 2017 Oct-Dec;10(4):244-249. (PMID: 29362600)
PLoS One. 2017 Jan 3;12(1):e0168980. (PMID: 28045971)
Mol Endocrinol. 2007 Nov;21(11):2785-94. (PMID: 17652184)
Int J Mol Sci. 2023 Aug 29;24(17):. (PMID: 37686185)
Curr Neuropharmacol. 2022;20(4):662-674. (PMID: 33882809)
Diab Vasc Dis Res. 2011 Apr;8(2):125-35. (PMID: 21562064)
Nat Rev Drug Discov. 2012 Aug;11(8):633-52. (PMID: 22850787)
Diabetes. 2014 Sep;63(9):3141-8. (PMID: 24722248)
Life Sci. 2003 Dec 19;74(5):553-62. (PMID: 14623026)
BMJ Open Diabetes Res Care. 2016 Aug 04;4(1):e000227. (PMID: 27547413)
Metabolism. 2000 Nov;49(11):1390-4. (PMID: 11092499)
J Am Coll Cardiol. 2008 Sep 2;52(10):869-81. (PMID: 18755353)
Mol Ther. 2016 Oct;24(10):1848-1859. (PMID: 27480597)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Life Sci. 2000 Apr 14;66(21):2043-9. (PMID: 10823344)
Clin Med Insights Endocrinol Diabetes. 2011;4:1-12. (PMID: 22879789)
Curr Diab Rep. 2018 Oct 17;18(12):127. (PMID: 30328521)
J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):480-90. (PMID: 25689084)
Diabet Med. 1998 Jul;15(7):539-53. (PMID: 9686693)
Oman Med J. 2012 Jul;27(4):269-73. (PMID: 23071876)
Prog Mol Biol Transl Sci. 2014;121:165-215. (PMID: 24373238)
Innate Immun. 2014 Jul;20(5):519-28. (PMID: 24029145)
Pak J Pharm Sci. 2010 Jul;23(3):305-12. (PMID: 20566445)
Diabetes. 2016 Jan;65(1):53-61. (PMID: 26696639)
Eur J Pharmacol. 2018 Jul 5;830:95-104. (PMID: 29727638)
J Clin Endocrinol Metab. 2009 Dec;94(12):4810-9. (PMID: 19864452)
Am J Physiol Renal Physiol. 2006 Mar;290(3):F600-5. (PMID: 16159895)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
Braz J Med Biol Res. 2021 May 24;54(8):e10782. (PMID: 34037093)
فهرسة مساهمة: Keywords: Pioglitazone; Saxagliptin; diabetes mellitus; miRNA-29a; oxidative stress
تواريخ الأحداث: Date Created: 20231223 Latest Revision: 20231225
رمز التحديث: 20231225
مُعرف محوري في PubMed: PMC10741989
DOI: 10.3390/biomedicines11123300
PMID: 38137521
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines11123300